SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care
Phase of Trial: Phase III
Latest Information Update: 02 May 2014
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms SPRING
- Sponsors Boehringer Ingelheim
- 10 Jun 2017 Biomarkers information updated
- 27 Nov 2008 Actual patient number reported as 33 by ClinicalTrials.gov.
- 27 Nov 2008 Actual end date reported as October 2008 by Clinicaltrials.gov.